Phase 3 data of mdc-IRM first product based on MedinCell’s technology, shows significant improvements in patients with schizophrenia
15 November 2021
Phase 3 data of mdc-IRM, first product based on MedinCell’s […]
Our news
Bringing you the latest!
Investors
MedinCell: mdc-IRM’s Phase 3 data to be presented for the first time by Teva at Psych Congress 2021
21 October 2021
Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia
31 August 2021
Participation terms in the MedinCell Combined General Meeting
4 August 2021
MedinCell: mdc-CWM clinical phase 3 will start in 2021
25 March 2021
Covid-19: MedinCell publishes an extensive Ivermectin Safety Expert Analysis
5 March 2021
Covid-19: MedinCell presents positive first results from the clinical trial aiming at validating the safety of continuous administration of Ivermectin
17 December 2020
MedinCell publishes its first-half 2020/2021 financial results (April – September 2020): operating expenses and portfolio development in line with expectations
9 December 2020